Published in AIDS Weekly, May 10th, 2010
"Numerate has demonstrated that its novel technology can deliver active lead compounds in a timely and cost-effective manner. We have decided not to pursue further development of these compounds for internal reasons," said Omar K. Haffar, Ph.D., Presidio Founder, President and Chief Executive Officer, who added, "Based on our positive experience, we would not hesitate to work with Numerate in the future."
Guido Lanza, President and Chief Executive Officer of Numerate,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.